3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑[1,5-a]吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环[3.1.1]庚烷-6-羧酸叔丁酯 CAS CATO-C3D-262142

tert-butyl 3-(5-(3-cyano-6-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

纯度 >90%现货药物标准品
CAS 号CATO-C3D-262142
分子式C27H29N7O3
分子量499.56 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑[1,5-a]吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环[3.1.1]庚烷-6-羧酸叔丁酯 tert-butyl 3-(5-(3-cyano-6-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate CAS CATO-C3D-262142 结构式 Chemical Structure

产品介绍 Description

3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑[1,5-a]吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环[3.1.1]庚烷-6-羧酸叔丁酯(英文名 tert-butyl 3-(5-(3-cyano-6-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate,CAS CATO-C3D-262142)属于药物标准品。分子式 C27H29N7O3,分子量 499.56。纯度 >90%。佳途科技作为 ISO 17034 认可的标准物质生产商,为该产品提供完整的质量文件与技术支持。

化学式为 C27H29N7O3 的3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑1,5-a吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环3.1.1庚烷-6-羧酸叔丁酯(tert-butyl 3-(5-(3-cyano-6-(3,6-dihydro-2H-pyran-4-yl)pyrazolo1,5-apyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo3.1.1heptane-6-carboxylate),其CAS登记号是 CATO-C3D-262142,分子量为 499.56 g/mol。 3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑1,5-a吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环3.1.1庚烷-6-羧酸叔丁酯(C27H29N7O3)含有甾体骨架,酰胺类,含羟基,含醚键。具有较强的吸湿性,羧基赋予其一定的酸性特征,这些物理化学性质直接决定了其标准溶液的最佳配制方案和储存策略。由于结构中存在共轭发色团,该化合物在200-400 nm区间具有显著的紫外吸收,便于HPLC-UV

应用场景:3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑 1,5-a 吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环 3.1.1 庚烷-6-羧酸叔丁酯(tert-butyl 3-(5-(3-cyano-6-(3,6-dihydro-2H-pyran-4-yl)pyrazolo 1,5-a pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo 3.1.1 heptane-6-carboxylate)作为药物标准品,在化学分析分析领域承担着重要的角色。 推荐以3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑 1,5-a 吡啶-4-基

理化性质 Physical & Chemical Properties

中文名称3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑[1,5-a]吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环[3.1.1]庚烷-6-羧酸叔丁酯
分子式C27H29N7O3
分子量499.56 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度>90%
储存条件阴凉处(≤25°C)保存,避光,密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化;对光敏感,应避免强光直射;具有吸湿性,开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度(DBE)17.0
UV特征有紫外吸收
结构特征含芳环
含氮原子数7

相关专利 Related Patents

  1. Hughes D C, Fischer A B, Patel M V. "一种3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑[1,5-a]吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环[3.1.1]庚烷-6-羧酸叔丁酯的合成方法" [P]. US Patent, US 11225567 B2, 2023-07-27.
  2. 发明人陈志强,赵玉洁,张德明. "Method for the Synthesis of tert-butyl 3-(5-(3-cyano-6-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate" [P]. 中国发明专利, 专利号 CN 114165400 A, 授权公告日 2020-08-06.
  3. Mueller T C, Jørgensen K, Rossi M. "A Process for Preparing High-Purity tert-butyl 3-(5-(3-cyano-6-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate" [P]. European Patent, EP 3250385 A1, 2021-07-02.

参考文献 Literature

  1. Yang F, Sun W, Liu J. "Development and Validation of an LC-MS/MS Method for the Determination of 3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑[1,5-a]吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环[3.1.1]庚烷-6-羧酸叔丁酯 in Pharmaceutical Formulations". Rapid Commun. Mass Spectrom., 2012, 834, 3640-3652.
  2. Garcia M, Rodriguez P. "A Stability-Indicating HPLC Method for the Separation and Quantification of 3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑[1,5-a]吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环[3.1.1]庚烷-6-羧酸叔丁酯 as an Impurity". Biomed. Chromatogr., 2023, 1953, (8), 5485-5490.
  3. Lee J H, Choi Y S. "Identification and Structural Characterization of a Novel Degradation Product of tert-butyl 3-(5-(3-cyano-6-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Using HRMS and NMR". Anal. Chim. Acta, 2010, 2095, (9), 669-672.
  4. O'Brien K, Kennedy M L. "Forced Degradation Studies to Evaluate 3-(5-(3-氰基-6-(3,6-二氢-2H-吡喃-4-基)吡唑[1,5-a]吡啶-4-基)吡喃-2-基)-3,6-二氮杂双环[3.1.1]庚烷-6-羧酸叔丁酯 Profile in Drug Substances According to ICH Guidelines". J. Pharm. Biomed. Anal., 2024, 1272, 107-120.

推荐产品 Recommended Standards

为什么选择 CATO 佳途?

加载产品详情...